High VEGFR-3-positive circulating lymphatic/vascular endothelial progenitor cell level is associated with poor prognosis in human small cell lung cancer

Clinical Cancer Research

Volumn 15, Issue 5, 2009, Pages 1741-1746

  Bogos, Krisztina ^a,b   Renyi Vamos, Ferenc ^a,d,g   Dobos, Judit ^a,e   Kenessey, Istvan ^e,f   Tovari, Jozsef ^a,e   Timar, Jozsef ^f   Strausz, Janos ^c   Ostoros, Gyula ^b   Klepetko, Walter ^g   Ankersmit, Hendrik Jan ^g   Lang, Gyorgy ^g   Hoda, Mir Alireza ^g   Nierlich, Patrick ^g   Dome, Balazs ^a,b,g,h  

^a Tumor Biology   (Hungary)

^b Departments of Thoracic Oncology   (Hungary)

^c NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

^d Departments of Surgery   (Hungary)

^e NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^f SEMMELWEIS UNIVERSITY   (Hungary)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h National Institute of Pulmonology   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIBODY; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER STAGING; CELL GROWTH; CONTROL GROUP; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; STEM CELL; TUMOR CLASSIFICATION; VASCULAR ENDOTHELIUM;

ADULT; AGED; BONE MARROW; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; LUNG; LUNG NEOPLASMS; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MALE; MIDDLE AGED; PROGNOSIS; SMALL CELL LUNG CARCINOMA; STEM CELLS; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 63449135769     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1372     Document Type: Article

References (41)

1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-44.
2. Simon GR, Turrisi A; American College of Chest Physicians. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:324-39S.
3. Döme B, Hendrix MJ, Paku S, Tóvári J, Tímár J. Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol 2007;170:1-15.
4. Achen MG, Mann GB, Stacker SA. Targeting lymphangiogenesis to prevent tumour metastasis. Br J Cancer 2006;94:1355-60.
5. Van der Auwera I, Cao Y, Tille JC, et al. First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer 2006;95:1611 -25.
6. Stacker SA, Baldwin ME, Achen MG. The role of tumor lymphangiogenesis in metastatic spread. FASEB J 2002;16:922-34.
7. Salven P, Mustjoki S, Alitalo R, Alitalo K, Rafii S. VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood 2003;101:168-72.
8. Kerjaschki D, Huttary N, Raab I, et al. Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants. Nat Med 2006;12:230-4.
9. Religa P, Cao R, Bjorndahl M, Zhou Z, Zhu Z, Cao Y. Presence of bone marrow-derived circulating progenitor endothelial cells in the newly formed lymphatic vessels. Blood 2005;106:4184-90.
10. Ho JW, Pang RW, Lau C, et al. Significance of circulating endothel al progen tor cells n hepatocellular carcinoma. Hepatology 2006;44:836-43.
11. Massa M, Rosti V, Ramajoli I, et al. Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J Clin Oncol 2005;23:5688-95.
12. Furstenberger G, von Moos R, Lucas R, et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 2006;94:524-31.
13. Zhang H, Vakil V, Braunstein M, et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005;105:3286 -94.
14. Dome B, Dobos J,Tovari J, et al. Circulating bone marrow-derived endothelial progenitor cells: Characterization, mobilization, and therapeutic considerations in malignant disease. Cytometry A 2008;73:186-93.
15. Dome B, Timar J, Dobos J, et al. Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res 2006;66:7341-7.
16. Pircher A, Kahler CM, Skvortsov S, et al. Increased numbers of endothelial progenitor cells in peripheral blood and tumor specimens in non-small cell lung cancer: a methodological challenge and an ongoing debate on the clinical relevance. Oncol Rep 2008;19:345-52.
17. Stahel R, Ginsberg R, Havemann K, et al. Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer1989;5:119-26.
18. Fadini GP, Schiavon M, Cantini M, et al. Circulating progenitor cells are reduced in patients with severe lung disease. Stem Cells 2006;24:1806-13.
19. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2007. Available from: http://www.goldcopd.org.
20. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17:343-6.
21. Hristov M, Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med 2004;8:498-508.
22. Eguchi M, Masuda H, Asahara T. Endothelial progenitor cells for postnatal vasculogenesis. Clin Exp Nephrol 2007;11:18-25.
23. Shepherd FA, Crowley J, Van Houtte P, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007;2:1067 -77.
24. Jackson DG. Lymphatic markers, tumour lymphangiogenesis and lymph node metastasis. Cancer Treat Res 2007;135:39-53.
25. Sundar SS, Ganesan TS. Role of lymphangiogenesis in cancer. J Clin Oncol 2007;25:4298-307.
26. Su JL,Yen CJ, Chen PS, et al. The role of theVEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer 2007;96:541-5.
27. He Y, Kozaki K, Karpanen T, et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 2002;94:819-25.
28. Khakoo AY, Finkel T. Endothelial progenitor cells. Annu Rev Med 2005;56:79 -101.
29. Liew A, Barry F, O'Brien T. Endothelial progenitor cells: diagnostic and therapeutic considerations. Bio-Essays 2006;28:261 -70.
30. Sedivy R, Beck-Mannagetta J, Haverkampf C, Battistutti W, Honigschnabl S. Expression of vascular endothelial growth factor-C correlates with the lymphatic microvessel density and the nodal status in oral squamous cell cancer. J Oral Pathol Med 2003;32:455 -60.
31. Tsurusaki T, Kanda S, Sakai H, et al. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph nodemetastasis. Br J Cancer 1999;80:309 -13.
32. Kitadai Y, Amioka T, Haruma K, et al. Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int J Cancer 2001;93:662 -6.
33. Schietroma C,Cianfarani F, Lacal PM, et al. Vascular endothelial growth factor-C expression correlates with lymph node localization of human melanoma metastases. Cancer 2003;98:789-97.
34. Yonemura Y, Endo Y, Fujita H, et al. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res 1999;5:1823-9.
35. Li Q, Dong X, Gu W, Qiu X, Wang E. Clinical significance of co-expression of VEGF-C and VEGFR-3 in non-small cell lung cancer. Chin Med J (Engl) 2003;116:727-30.
36. Naumnik W, Izycki T, Swidzinska E, Ossoliniska M, Chyczewska E. Serum levels of VEGF-C, VEGF-D, sVEGF-R2 in patients with lung cancer during chemotherapy. Oncol Res 2007;16:445 -51.
37. Kimura H, Kato H,Tanaka N, et al. Preoperative serum vascular endothelial growth factor-C (VEGF-C) levels predict recurrence in patients with esophageal cancer. Anticancer Res 2008;28:165-9.
38. Wang TB, Deng MH, Qiu WS, Dong WG. Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J Gastroenterol 2007;13:1794-7.
39. Yu XM, Lo CY, Lam AK, Leung P, Luk JM. Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma. Ann Surg 2008;247:483 -9.
40. Vihinen PP, Hilli J, Vuoristo MS, Syrjänen KJ, Kähäri VM, Pyrhönen SO. Serum VEGF-C is associated with metastatic site in patients with malignant melanoma. Acta Oncol 2007;46:678-84.
41. Tamura M, Ohta Y. Serum vascular endothelial growth factor-C level in patients with primary nonsmall cell lung carcinoma: a possible diagnostic tool for lymph node metastasis. Cancer 2003;98:1217 -22.